Condition
Novel COVID-19-Infected Pneumonia
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Unknown2
Clinical Trials (2)
Showing 2 of 2 trials
NCT05688839Phase 2UnknownPrimary
A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
NCT05686629Phase 2UnknownPrimary
An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
Showing all 2 trials